Fozza Claudio, Murtas Andrea, Caocci Giovanni, La Nasa Giorgio
Department of Medical, Surgical and Experimental Sciences, University of Sassari, Viale San Pietro 12, 07100 Sassari, Italy.
Department of Medical Sciences, University of Cagliari, Cagliari, Italy.
Leuk Res. 2022 Jun;117:106856. doi: 10.1016/j.leukres.2022.106856. Epub 2022 May 2.
Around one third of patients with myelodysplastic syndromes (MDS) suffer from concomitant autoimmune disorders (AD). However the actual burden of such an association appears to be quite heterogeneous in different studies probably due to variable criteria in selecting both MDS patients and subtypes of AD. Moreover, both the prognostic implications and the potential applications of specific therapeutic approaches in this patient subgroup are still at least partially under debate. The present review will try to shed some further light on the clinical association between MDS and AD in order to better delineate its prognostic significance and to suggest potential therapeutic algorithms available for these patients.
约三分之一的骨髓增生异常综合征（MDS）患者伴有自身免疫性疾病（AD）。然而，在不同研究中，这种关联的实际负担似乎差异很大，这可能是由于在选择MDS患者和AD亚型时标准不同所致。此外，这一患者亚组中特定治疗方法的预后意义和潜在应用仍至少部分存在争议。本综述将试图进一步阐明MDS与AD之间的临床关联，以便更好地界定其预后意义，并提出适用于这些患者的潜在治疗方案。
